F M Muggia|T Fojo - JoVE Visualize

Showing results (141-150 of 323) with videos related to

Pageof 33

Sort By:

Environmental Health Perspectives|November 1, 1992

Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitroM Dabholkar, L Bradshaw, R J Parker, et al.

Carcinogenesis|July 1, 1991

Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometryR J Parker, I Gill, R Tarone, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998

Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumorsA A Garcia, S Keren-Rosenberg, D Parimoo, et al.

Seminars in Oncology|August 1, 1995

Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trialsF M Muggia, D Vafai, R Natale, et al.

Cancer Investigation|January 1, 1995

Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinomaM Turrill, D V Spicer, A S Kelley, et al.

American Journal of Clinical Oncology|October 1, 1985

A phase II study of bisantrene in advanced refractory breast cancer. An Eastern Cooperative Oncology Group pilot studyK J Pandya, F M Muggia, R T Skeel, et al.

The Oncologist|October 22, 2025

Cancer Interception During Treatment: Using Growth Kinetics to Create a Continuous Variable for Assessing Disease ResponseMengxi Zhou, Antonion T Fojo, Lawrence H Schwartz, et al.

Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 14, 1997

[Expression of ATP binding cassette superfamily (multidrug resistance-1, multidrug resistance-associated protein, human canalicular multispecific organ anion transporter) mRNA in etoposide and m-AMSA resistant cell lines]Y Matsumoto, M Matsumoto, M Minemura, et al.

Cancer Research|August 12, 1998

Bcl-xL is phosphorylated in malignant cells following microtubule disruptionM S Poruchynsky, E E Wang, C M Rudin, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003

Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactionsA Chanan-Khan, J Szebeni, S Savay, et al.

Pageof 33

Showing results (141-150 of 323) with videos related to

Sort By:

Pageof 33

Environmental Health Perspectives|November 1, 1992

Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitroM Dabholkar, L Bradshaw, R J Parker, et al.

Carcinogenesis|July 1, 1991

Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometryR J Parker, I Gill, R Tarone, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998

Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumorsA A Garcia, S Keren-Rosenberg, D Parimoo, et al.

Seminars in Oncology|August 1, 1995

Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trialsF M Muggia, D Vafai, R Natale, et al.

Cancer Investigation|January 1, 1995

Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinomaM Turrill, D V Spicer, A S Kelley, et al.

American Journal of Clinical Oncology|October 1, 1985

A phase II study of bisantrene in advanced refractory breast cancer. An Eastern Cooperative Oncology Group pilot studyK J Pandya, F M Muggia, R T Skeel, et al.

The Oncologist|October 22, 2025

Cancer Interception During Treatment: Using Growth Kinetics to Create a Continuous Variable for Assessing Disease ResponseMengxi Zhou, Antonion T Fojo, Lawrence H Schwartz, et al.

Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 14, 1997

[Expression of ATP binding cassette superfamily (multidrug resistance-1, multidrug resistance-associated protein, human canalicular multispecific organ anion transporter) mRNA in etoposide and m-AMSA resistant cell lines]Y Matsumoto, M Matsumoto, M Minemura, et al.

Cancer Research|August 12, 1998

Bcl-xL is phosphorylated in malignant cells following microtubule disruptionM S Poruchynsky, E E Wang, C M Rudin, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003

Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactionsA Chanan-Khan, J Szebeni, S Savay, et al.

Pageof 33